Vesteck, Inc., a West Chester, Pa.-based early-stage medical device company, held the initial close on $4.3M of Series A financing, which includes conversion of all existing convertible notes.
The New World Angels of S. Florida, led the Series A round with a $1.1m investment, joined by Florida-based DeepWork Capital and Ocean Azul Partners, as well as a number of Philadelphia-based investors, including Ben Franklin Technology Partners of Southeastern Pennsylvania, Robin Hood Ventures and the Delaware Crossing Investor Group.
The company intends to use the funds for the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
Led by Chief Medical Officer Dr. David H. Deaton and CEO Joe Rafferty, Vesteck is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Their first product, the “Suture-Tight” nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients. The company has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
FinSMEs
25/08/2021